Do you want to read an article? Please log in or register.
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
Further Publications
Related content
Further Publications
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
Eur J Cancer.
Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J
doi: 10.1016/j.ejca.2020.03.017.
Further Publications
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
JAMA Oncol.
Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J
doi: 10.1001/jamaoncol.2020.0726.
Gastrointestinal CancerSkin Cancer
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Cancer Treat Rev.
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C
doi: 10.1016/j.ctrv.2017.06.002.
Lung, Respiratory and Thoracic Cancer
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
JAMA Oncol.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J
doi: 10.1001/jamaoncol.2020.5012.
Radio-Oncology
Safety of Thoracic Radiotherapy in Patients with Prior Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Ann Oncol.
Shaverdian N, Beattie J, Thor M, Offin M, Shepherd AF, Gelblum DY, Wu AJ, Simone CB 2nd, Hellmann MD, Chaft JE, Rimner A, Gomez DR
doi: 10.1016/j.annonc.2020.09.016.
Non-Malignant Blood Disorders
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Eur J Cancer.
Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O
doi: 10.1016/j.ejca.2019.07.014.
RECOMMENDED
Radio-Oncology
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy
★ 1
Recommended by
Alexander Meisel, Faculty Member
Eur J Cancer.
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M
doi: 10.1016/j.ejca.2020.09.001.Visit the original publication at ncbi.nlm.nih.gov
Further Publications
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
JAMA Oncol.
Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O
doi: 10.1001/jamaoncol.2019.1022.
Lung, Respiratory and Thoracic CancerSkin Cancer
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Reference
doi: 10.1016/j.ejca.2018.11.009.